Clozapine-induced agranulocytosis: Genetic risk factors and an immuno-toxic explanatory model;Door clozapine geïnduceerde agranulocytose: Genetische en immunologische verklaringen

Tijdschrift voor Psychiatrie

Volumn 48, Issue 4, 2006, Pages 295-302

  Guzelcan Y ^a   Scholte, W F ^b  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Agranulocytosis; Clozapine; Genetic predisposition to disease; Risk factors

Indexed keywords

CLOZAPINE; DIHYDRONICOTINAMIDE RIBOSIDE QUINONE OXIDOREDUCTASE; HEAT SHOCK PROTEIN 70; MICROSATELLITE DNA; OXIDOREDUCTASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALLELE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG INDUCED DISEASE; GENETIC RISK; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOTOXICITY; REVIEW; SCHIZOPHRENIA;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; RISK FACTORS; SCHIZOPHRENIA;

EID: 33646045046     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Amar, A., Segman, R.H., Shtrussberg, S., e.a. (1998). An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQJB1*0201. The International Journal of Neuropsychopharmacology, 1, 41-44.
2. Atkin, K., Kendall, F., Gould, D., e.a. (1996). Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. The British Journal of Psychiatry, 169, 483-488.
3. Azorin, J.M., Spiegel, R., Remington, G., e.a. (2001). A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. The American Journal of Psychiatry, 158, 1305-1313.
4. Combs, M.D., Perry, P.J., & Bever, K.A. (1997). N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy, 17, 1300-1304.
5. Corzo, D., Yunis, J.J., Salazar, M., e.a. (1995). The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood, 86, 3835-3840.
6. Corzo, D., Yunis, J.J., Yunis, E.J., e.a. (1994). HSP70-29.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. The Journal of Clinical Psychiatry, 55(Suppl. B), 149-152.
7. Deliliers, G.L., Servida, F., Lamorte, G., e.a. (1998). In vitro effect of clozapine on hemopoietic progenitor cells. Haematologica, 83, 882-889.
8. Dettling, M., Cascorbi, I., Roots, I., e.a. (2001a). Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Archives of General Psychiatry, 58, 93-94.
9. Dettling, M., Schaub, R.T., Mueller-Oerlinghausen, B., e.a. (2001b). Further evidence of human leukocyre antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics, 11, 135-141.
10. Diaz, P., & Hogan, T.P. (2001). Granulocytopenia with clozapine and quetiapine. The American Journal of Psychiatry, 158, 651.
11. Gerson, S.L., Arce, C., & Meltzer, H.Y. (1994). N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology, 86, 555-561.
12. Guest, I., Sokoluk, B., MacCrimmon, J., e.a. (1998). Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology, 131, 53-65.
13. Haynes, R.B., Wilczynski, N., McKibbon, K.A., e.a. (1994). Developing optimal search strategies for detecting clinically sound studies in MEDLINE. Journal of the American Medical Informatics Association, 1, 447-458.
14. Hong, X., & Wang, X. (2001). Agranulocytosis and neutropenia with typical and atypical neuroleptics. The American Journal of Psychiatry, 158, 1736-1737.
15. Honigfeld, G., Arellano, F., Sethi, J., e.a. (1998). Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. The Journal of Clinical Psychiatry, 59(Suppl. 3), 3-7.
16. Kane, J., Honigfeld, G., Singer, J., e.a. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
17. Lahdelma, L., Ahokas, A., Andersson, L.C., e.a. (1998). Association between HLA-A1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication. Tissue Antigens, 51, 200-203.
18. Lieberman, J.A., Yunis, J., Egea, E., e.a. (1990). HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47, 945-948.
19. Loosdrecht, A.A. van de, Faber, H.J., Hordijk, P., e.a. (1998). Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations. The Netherlands Journal of Medicine, 52, 26-29.
20. Melick, E.J. van, Touw, D.J., & Haak, H.L. (1995). Agranulocytose door clozapine: het belang van leukocytencontrole en het nut van bloedgroeifactoren. Nederlands Tijdschrift voor Geneeskunde, 139, 2437-2440.
21. Ostrousky, O., Meged, S., Loewenthal, R., e.a. (2003). NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens, 62, 483-491.
22. Pollmächer, T., Schuld, A., Kraus, T., e.a. (2001). Zur klinischen Relevanz der Wirkung von Clozapin auf die Freisetzung von Zytokinen und löslichen Zytokinrezeproren. Fortschritte der Neurologie- Psychiatrie, 69(Suppl. 2), S65-S74.
23. Schulte, P.F.J. (2001). De plaats van clozapine bij de behandeling van schizofrenie. Tydschrift voor Psychiatrie, 43, 715-720.
24. Sluys, M., Güzelcan, Y., Casteelen, G., e.a. (2004). Risperidone-induced leucopenia and neutropenia: a case report. European Psychiatry, 19, 117.
25. Sperner-Unterweger, B., Czeipek, I., Gaggl, S., e.a. (1998). Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. The British Journal of Psychiatry, 172, 82-84.
26. Steinwachs, A., Grohmann, R., Pedrosa, F., e.a. (1999). Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry, 32, 154-156.
27. Tolosa-Vilella, C., Ruiz-Ripoll, A., Mari-Alfonso, B., e.a. (2002). Olanzapine-induced agranulocytosis: a case report and review of the literature. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26, 411-414.
28. Tschen, A.C., Rieder, M.J., Oyewumi, L.K., e.a. (1999). The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clinical Pharmacology and Therapeutics, 65, 526-532.
29. Turbay, D., Lieberman, J., Alper, C.A., e.a. (1997). Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood, 89, 4167-4174.
30. Valevski, A., Klein, T., Gazit, E., e.a. (1998). HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. European Journal of Immunogenetics, 25, 11-13.
31. Vink, J. (2000). Koorts en leukocytose als voorbijgaande bijwerkingen van clozapine. Tijdschrift voor Psychiatrie, 42, 121-125.
32. Wahlbeck, K., Cheine, M., Essali, A., e.a. (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American Journal of Psychiatry, 156, 990-999.
33. Wickramanayake, P.D., Scheid, C., Josting, A., e.a. (1995). Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. European Journal of Medical Research, 1, 153-156.
34. Williams, D.P., Pirmohamed, M., Naisbitt, D.J., e.a. (2000). Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Molecular Pharmacology, 58, 207-216.
35. Yunis, J.J., Corzo, D., Salazar, M., e.a. (1995). HLA associations in clozapine-induced agranulocytosis. Blood, 86, 1177-1183.
36. Yunis, J.J., Lieberman, J., & Yunis, E.J. (1992). Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Safety, 7(Suppl. 1), 7-9.